

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: Tipifarnib(R115777) to Treat Children with NF1 and progressive plexiform neurofibromas (PNs)

OBJECTIVE OF STUDY *(please provide a description for PATIENTS interested in participating in the study):*

This study will examine whether the experimental drug R115777 can shrink or slow the growth of plexiform neurofibromas in children and young adults with neurofibromatosis type 1 (NF1) and determine what side effects are related to treatment.

MINIMUM ELIGIBILITY REQUIREMENTS *(please include age, location and gender):* Patients with NF1 and progressive plexiform neurofibromas between 3 and 25 years of age may be eligible for this study. Patients whose tumors can be successfully removed surgically may not participate in this study.

PARTICIPANT ACTIVITIES *(office visits, tests, take medications, etc):* Drug or placebo will be given every 12 hours for 21 days followed by 7-day rest period (one 28-day treatment cycle). Patients will keep a log of side effects. Tissue biopsy of easily accessible PNs before treatment begins. Photos of visible body surface tumors.

CONTACT INFORMATION: **COORDINATOR / CHAIR** *(please circle one)*

NAME/TITLE: Brigitte C. Widemann

AFFILIATION: National Cancer Institute – Pediatric Oncology Branch

MAILING ADDRESS: 9000 Rockville Pike
 Bethesda, MD 20892 USA

PHONE: 301.496.7387

Email ADDRESS:

WEBSITE *(for complete info):* http://clinicalstudies.info.nih.gov/detail/A_2001-C-0222.html